https://stm2.bookpi.org/PSRTC-V3/issue/feedPharmaceutical Science: Research Trends and Challenges Vol. 32026-11-18T11:53:43+00:00Open Journal Systemshttps://stm2.bookpi.org/PSRTC-V3/article/view/2173Immunomodulatory Activity of Atractylodes lancea in Healthy Volunteers and Model-Based Dose Selection for Cholangiocarcinoma Therapy2026-11-18T11:40:08+00:00Teerachat SaehengKesara Na-Bangchang[email protected]<p>This study brings together three distinct sources of evidence, which are kept separate throughout. (i) Previously reported healthy-volunteer data: in an earlier placebo-controlled phase I study in healthy Thai volunteers, <em>Atractylodes lancea</em> (Thunb.) DC. (AL) 1,000 mg once daily for 21 days significantly reduced the circulating levels of the cytokine panel measured (IL-2, IL-4, IL-6, IL-10, IL-17A, TNF-alpha and IFN-gamma) and altered several peripheral immune cell populations; that study did not define a maximum tolerated dose (MTD) or a regimen for phase IIA testing. (ii) New model-derived predictions generated in the present work: a whole-body physiologically based pharmacokinetic (PBPK) model of atractylodin, the principal constituent, was constructed in SimBiology, validated against the observed clinical concentration-time data (overall absolute average fold error 1.17) subjected to sensitivity analysis and subsequently used to simulate once-, twice- and four-times-daily regimens up to 10,000 mg/day. Predicted haematological toxicity (Emax model, with peripheral blood mononuclear cell inhibition as a surrogate) and predicted hepatotoxicity (unbound liver Cmax ratio, assuming a linear dose-enzyme relationship) were simulated in 100 virtual subjects. On these model-derived criteria, 500 mg four times daily was identified as the proposed first-in-human regimen, 2,500 mg four times daily as the model-predicted upper tolerated regimen (a prediction, not an observed MTD), and 1,500 or 2,000 mg once daily as the regimens proposed for phase IIA evaluation. (iii) Preliminary clinical observations: in the subsequent phase IIA trial, 2,000 mg once daily was associated with better disease control and survival than 1,000 mg once daily; these are preliminary, descriptive observations reported in full elsewhere, and no clinical methodology or statistical analysis is presented in this study. PBPK modelling combined with a toxicological approach can therefore assist dosage-regimen selection for clinical studies, including studies of herbal medicines, provided the model-derived values are confirmed clinically.</p>2026-11-18T00:00:00+00:00Copyright (c) 2026 Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.https://stm2.bookpi.org/PSRTC-V3/article/view/2174Dexmedetomidine and Esketamine in Perioperative Neurocognitive Disorders: Mechanistic Plausibility, Trial Evidence and Evidential Reliability2026-11-18T11:48:49+00:00P. Sharmila[email protected]<p><strong>Background:</strong> Perioperative neurocognitive disorders, including postoperative delirium, delayed neurocognitive recovery and postoperative neurocognitive disorder, are frequent and consequential in older surgical patients, yet no drug is recommended by guideline panels for routine prophylaxis. Dexmedetomidine, a selective alpha-2 adrenoceptor agonist, and esketamine, the S-enantiomer of ketamine and an N-methyl-D-aspartate receptor antagonist, have become the two most intensively investigated candidates, and the two drugs are increasingly administered together.</p> <p><strong>Aim and Scope:</strong> This critical narrative review examines whether the mechanistic rationale and clinical evidence for dexmedetomidine, esketamine and their combination justify claims of neurocognitive protection in adult surgical patients, with particular attention to the reliability of the underlying evidence.</p> <p><strong>Approach:</strong> Literature was identified through structured searches of bibliographic databases, full-text repositories, citation indexes and a trial registry, supplemented by citation tracking and checks for retractions, and was appraised qualitatively and synthesised thematically.</p> <p><strong>Principal Findings:</strong> Mechanistic support for both drugs derives largely from animal models and surrogate biomarkers, and the clinical relevance of these signals remains unproven. For dexmedetomidine, benefit against postoperative delirium appears most consistent when the drug acts during the postoperative or overnight period in older non-cardiac surgical patients, whereas large placebo-controlled cardiac trials have been neutral, and pooled estimates are sensitive to risk of bias, publication bias and the inclusion of subsequently retracted trials. For esketamine, meta-analyses report substantial reductions in early delirium, but the evidence base is geographically concentrated, short in follow-up, inconsistent across larger trials and difficult to reconcile with the neutral results of racemic ketamine. Evidence for the combination is limited to small single-centre trials that rarely isolate the contribution of each component.</p> <p><strong>Unresolved Questions:</strong> Optimal timing, dose, patient selection, effects on cognition beyond 30 days, and the roles of sleep, analgesia and mood as mediators remain uncertain.</p> <p><strong>Conclusion:</strong> Neither agent, alone or in combination, can presently be regarded as an established neuroprotective intervention. Adequately powered, multicentre, prospectively registered trials with standardised outcome ascertainment and longer cognitive follow-up are required before routine prophylactic use can be justified.</p>2026-11-18T00:00:00+00:00Copyright (c) 2026 Author(s). The licensee is the publisher (BP International).https://stm2.bookpi.org/PSRTC-V3/article/view/2175Network Pharmacology of Atractylodes lancea in Advanced Intrahepatic Cholangiocarcinoma: Integrating Patient Transcriptomics with Molecular Docking2026-11-18T11:53:43+00:00Teerachat SaehengKesara Na-Bangchang[email protected]<p>Cholangiocarcinoma (CCA) is an aggressive cancer of the biliary tract associated with a substantial disease burden and a poor prognosis, largely owing to late diagnosis and a limited response to current chemotherapy. Network pharmacology (molecular networking) is a bioinformatic approach that can reveal how complex medicines and new drug candidates act on multiple targets simultaneously. This study applies the approach to <em>Atractylodes lancea</em> (Thunb.) DC. (AL), a botanical candidate for advanced intrahepatic CCA (iCCA), and to its three main bioactive constituents—atractylodin, β-eudesmol and hinesol. Transcriptomic data from a phase IIA clinical trial were used to identify genes whose expression changed in patients treated with AL compared with those receiving standard supportive care, and genes that distinguished progressive from non-progressive disease. A molecular network of AL's signalling pathways was then built in Cytoscape. Fifty-two key target genes were identified. The most highly connected network hubs were <em>TNF</em> (TNF-α), <em>PIK3CA</em> and <em>NRAS</em>, and false discovery rate (FDR) analysis ranked PI3K/AKT signalling, natural killer (NK) cell-mediated cytotoxicity and apoptosis as the three most significantly enriched pathways. In molecular docking, hinesol showed stronger predicted binding to these targets than the other AL constituents and the standard anti-CCA drugs gemcitabine and 5-fluorouracil (5-FU). The work illustrates the value of network analysis for understanding the multi-target action of herbal medicines and links AL to several interconnected pathways of tumour progression, supporting further investigation of its therapeutic potential for advanced iCCA.</p>2026-11-18T00:00:00+00:00Copyright (c) 2026 Author(s). The licensee is the publisher (BP International).